Terns Pharmaceuticals Receives Breakthrough Therapy Designation for TERN-701 in CML
Terns Pharmaceuticals Awarded FDA Breakthrough Therapy Designation for TERN-701 in Chronic Myeloid Leukemia
Key Highlights
-
Breakthrough Therapy Designation Granted: Terns Pharmaceuticals, Inc. (Nasdaq: TERN) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to TERN-701, an oral allosteric BCR::ABL1 inhibitor.
-
Target Patient Population: The designation is for adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic phase who do not have the T315I mutation and have previously been treated with two or more tyrosine kinase inhibitors (TKIs).
-
Positive Clinical Data: The BTD was granted based on positive data from the ongoing Phase 1/2 CARDINAL clinical trial, where TERN-701 demonstrated promising activity, including high rates of major molecular response and deep molecular response at week 24, even in patients with high disease burden and prior allosteric TKI exposure.
-
Safety Profile: The majority of treatment-emergent adverse events in the CARDINAL trial were low grade, with a low incidence of severe adverse events and treatment discontinuations.
-
Potential for Accelerated Development: The Breakthrough Therapy Designation is expected to expedite development and regulatory review, potentially accelerating TERN-701’s path to a pivotal trial and eventual commercialization.
-
Strategic Importance: The announcement comes in the wake of a recent agreement for Merck to acquire Terns Pharmaceuticals, which could further accelerate the development and commercialization of TERN-701.
Details Investors Should Know
The granting of Breakthrough Therapy Designation by the FDA is a significant regulatory milestone and strongly signals the agency’s recognition of TERN-701’s potential to address a serious unmet medical need in CML, especially for patients with limited remaining treatment options. This could have a substantial impact on Terns Pharmaceuticals’ valuation and investor sentiment.
The designation not only expedites the development and review process—potentially leading to earlier approval and commercialization—but also enhances the company’s strategic value, especially considering the recently announced acquisition by Merck. This combination of positive clinical data, regulatory momentum, and corporate activity is highly price sensitive and could drive significant share price movement.
TERN-701 is positioned as a “best-in-disease” candidate, aiming to improve upon the efficacy, safety, and convenience of current CML therapies. The promising clinical trial outcomes, with faster and deeper molecular responses compared to existing TKIs and an encouraging safety profile, further strengthen the drug’s commercial potential.
Forward-Looking Statements and Risks
Investors should be aware that despite these promising developments, Terns Pharmaceuticals remains a clinical-stage company. The future success of TERN-701 is subject to risks inherent in drug development, including the outcomes of ongoing and future clinical trials, regulatory decisions, competition, and the ability to execute on strategic partnerships or commercial launches. The company’s forward-looking statements are subject to various uncertainties detailed in its public filings.
About Terns Pharmaceuticals
Terns Pharmaceuticals is a clinical-stage oncology company focused on delivering high-impact medicines by reimagining known biology. The company’s lead asset, TERN-701, is a highly selective, oral, allosteric BCR::ABL1 inhibitor with the potential for best-in-class efficacy, safety, and convenience for the treatment of chronic myeloid leukemia.
For more information, investors are directed to visit www.ternspharma.com.
Investor Contacts
Disclaimer: This article is for informational purposes only and does not constitute investment advice. All forward-looking statements are subject to risks and uncertainties, and actual results may differ materially. Investors should consult the company’s filings with the Securities and Exchange Commission for further information and risk disclosures.
View Terns Pharmaceuticals, Inc. Historical chart here
